Latest News and Press Releases

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present...

Torino, Italy, October 7 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class...

NEW YORK, July 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April...

Block & Leviton is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. Investors should contact the firm.

Sagapixel reports “GLP-1” has overtaken “Ozempic” in search volume, signaling a major shift in patient awareness and provider marketing and SEO strategy.

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Re

- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration...

Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22

New York, May 10, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: The growing challenges with traditional weight loss methods and why most diets failWhat GLP-1 receptor agonists like...